235 related articles for article (PubMed ID: 18069922)
1. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
Gaumann A; Schlitt HJ; Geissler EK
Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
3. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
4. Fighting malignancy in organ transplant recipients.
Geissler EK
Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298
[TBL] [Abstract][Full Text] [Related]
5. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Geissler EK
Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
[TBL] [Abstract][Full Text] [Related]
6. [Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].
Infante B; Stallone G; Schena A; Maiorano A; Gesualdo L; Schena FP; Grandaliano G
G Ital Nefrol; 2006; 23(4):389-95. PubMed ID: 17063439
[TBL] [Abstract][Full Text] [Related]
7. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors.
Cruzado JM
Transplant Rev (Orlando); 2008 Jan; 22(1):73-81. PubMed ID: 18631860
[TBL] [Abstract][Full Text] [Related]
8. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus in renal transplantation.
Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
[TBL] [Abstract][Full Text] [Related]
10. Minimizing the risk of posttransplant malignancy.
Campistol JM
Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
[TBL] [Abstract][Full Text] [Related]
11. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.
Paoletti E; Cannella G
Transplant Proc; 2009; 41(6 Suppl):S3-5. PubMed ID: 19651293
[TBL] [Abstract][Full Text] [Related]
13. The pleiotropic effects of mTor inhibitors.
Ponticelli C
J Nephrol; 2004; 17(6):762-8. PubMed ID: 15593048
[TBL] [Abstract][Full Text] [Related]
14. Controlling the incidence of infection and malignancy by modifying immunosuppression.
Soulillou JP; Giral M
Transplantation; 2001 Dec; 72(12 Suppl):S89-93. PubMed ID: 11833147
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors in hematologic malignancies.
Dancey JE
Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
[TBL] [Abstract][Full Text] [Related]
16. De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.
Flechner S; Friend P; Campistol J; Weir M; Diekmann F; Russ G
Transplant Proc; 2009; 41(6 Suppl):S42-4. PubMed ID: 19651296
[No Abstract] [Full Text] [Related]
17. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
Chapman JR; Valantine H; Albanell J; Arns WA; Campistol JM; Eisen H; Frigerio M; Lehmkuhl H; Marcen R; Morris R; Nashan B; Pascual J; Pohanka E; Segovia J; Zuckermann A
Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
[TBL] [Abstract][Full Text] [Related]
18. Evidence for immunosuppression in lung transplantation.
Hopkins PM; McNeil K
Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
[TBL] [Abstract][Full Text] [Related]
20. Strategies for minimizing immunosuppression in kidney transplantation.
Kirk AD; Mannon RB; Swanson SJ; Hale DA
Transpl Int; 2005 Jan; 18(1):2-14. PubMed ID: 15612977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
